Company news
Abbott Secures CE Mark for Cologuard Plus Colorectal Cancer Screening Test
Abbott announced that the Cologuard Plus stool-based DNA colorectal cancer screening test has received EU IVDR CE Mark, a key step toward European market entry. In the BLUE-C study, it showed 95% sensitivity and 94% specificity for colorectal cancer.
Published · Updated · Source: Surgical Robotics Technology · AI translation
IllustrationAbbott announced that the Cologuard Plus test has received CE Mark under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR), marking an important step toward making the noninvasive colorectal cancer screening test available in Europe. The test analyzes DNA markers and blood in stool associated with colorectal cancer and precancerous lesions, and does not require bowel preparation, dietary restrictions or sedation. Abbott plans to introduce the test in select European markets, with timing and availability varying by country based on local healthcare pathways, reimbursement and operational readiness.
Cologuard Plus was evaluated in the prospective, multicentre BLUE-C study of more than 20,000 participants. Among the U.S. screening population, the test demonstrated 95% sensitivity for colorectal cancer at 94% specificity, 43% sensitivity for advanced precancerous lesions, and 74% sensitivity for high-grade dysplasia, with up to a 40% reduction in false-positive results compared with the original Cologuard test. This information comes from the original source and was organized by AI.
Read the original sourceRelated news
- Hello Robotaxi Adjusts Organizational Structure, CEO Directly Oversees Model and Data Closed-Loop
- Medtronic's Hugo Surgical Robot Wins FDA Clearance for General Surgery
- Medtronic Wins FDA Clearance for Hugo RAS System in General Surgery
- GM Plans to Expand North American Factory Automation by 20% by 2028